Cost of screening strategies for kidney disease before intravenous contrast administration

Netherlands Journal of Medicine

Volumn 72, Issue 5, 2014, Pages 271-280

  Moos, S I ^a   de Weijert, R S ^a   Nagan, G ^a   Stoker, J ^a   Bipat, S ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Computed tomography; Contrast induced nephropathy; Cost effective; Kidney disease; Prevention

Indexed keywords

CREATININE; IOMEPROL; IOPROMIDE; METFORMIN; CONTRAST MEDIUM;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCED COMPUTED TOMOGRAPHY; CONTRAST INDUCED NEPHROPATHY; COST BENEFIT ANALYSIS; CREATININE BLOOD LEVEL; DIABETES MELLITUS; ESTIMATED GLOMERULUS FILTRATION RATE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INTERVIEW; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PERTHES DISEASE; RISK FACTOR; SCREENING TEST; ACUTE KIDNEY INJURY; AGED; CHEMICALLY INDUCED; COST OF ILLNESS; ECONOMICS; HEALTH CARE COST; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION TEST; MIDDLE AGED; NETHERLANDS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRODUCTIVITY; TRAFFIC AND TRANSPORT;

ACUTE KIDNEY INJURY; ADMINISTRATION, INTRAVENOUS; AGED; CONTRAST MEDIA; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DIRECT SERVICE COSTS; EFFICIENCY; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; NETHERLANDS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TRANSPORTATION;

EID: 84902493660     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. RIVM. Het aantal CT-onderzoeken voor de jaren 1991 tot en met 2011. 2012. Webpage: http://www.rivm.nl/Onderwerpen/M/Medische_Straling.
2. Stacul F, van der Molen AJ, Reimer P, et al. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol. 2011;21:2527-41.
3. Owen R, Hiremath S, Myers A, Fraser-Hill M, Barrett B. Consensus Guidelines for the Prevention of Contrast Induced Nephropathy. Canadian Assocication of Radiologists. 2011. Webpage: http://www.car.ca/uploads/ standards%20guidelines/20110617_en_prevention_cin.pdf.
4. Wetzels JFM, Bronzwaer JGF, Geenen RWF, et al. Voorkomen van nierinsufficiëntie bij intravasculair gebruik van jodiumhoudende contrastmiddelen. 2009. Webpage: http://www.vmszorg.nl/_page/ vms_inline?nodeid=4667&subjectid=6704&configid=6492.
5. Cohan RH, Dillman JR, Hartman RP, et al. Amercan College of Radiology Manual on Contrast Media Version 9 ACR Manual on Contrast Media, American College of Radiology, 2013. Webpage: http://www.acr.org/~/ media/ACR/Documents/PDF/QualitySafety/Resources/Contrast%20 Manual/2013_Contrast_Media.pdf.
6. Thomas M, Davies A, Dawnay A, et al. Acute kidney injury prevention, detection and management of acute kidney injury up to the point of renal replacement therapy. NICE Clinical Guidelines. (August). 2013. Webpage: http://www.nice.org.uk/nicemedia/live/14258/65056/65056.pdf.
7. Lewington A, Mac Tier R, Hoefield R, Sutton A, Smith D. Prevention of Contrtast Induced Acute Kidney Injury (CI-AKI) In Adult Patients. The Renal Association, British Cardiovascular Intervention Society and Royal College of Radiologists. 2013. Webpage: http://www.rcr.ac.uk/docs/ radiology/pdf/2013_RA_BCIS_RCR.pdf.
8. Van Dijk R, van Croonenborg JJ, van Logtesteijn SI, et al. Voorzorgsmaatregelen bij jodiumhoudende contrastmiddelen. CBO Richtlijnen. 2007. Webpage: http://www.nvpc.nl/uploads/ stand/2617_12_07_Voorzorgsmaatregelen.pdf.
9. Board of the faculty of Clinical Radiology. Standards for intravascular contrast agent administration to adult patients Second edition. R Coll Clin Radiol. 2011:3-15.
10. Moos SI, Stoker J, Beenen LFM, Flobbe K, Bipat S. The prevention of contrast-induced nephropathy in dutch hospitals. Neth J Med. 2013;71:48-54.
11. Fishman EK, Reddan D. What are radiologists doing to prevent contrastinduced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography. Acta Radiol. 2008;49:310-20.
12. Elicker BM, Cypel YS, Weinreb JC. IV contrast administration for CT: a survey of practices for the screening and prevention of contrast nephropathy. Am J Roentgenol. 2006;186:1651-8.
13. Katzberg RW, Newhouse JH. Intravenous contrast medium-induced nephrotoxicity: is the medical risk really as great as we have come to believe? Radiology. 2010;256:21-8.
14. De Boer JE, Boomkamp MD, Broekhuijsen F, et al. Farmacotherapeutisch Kompas. College Voor Zorgverzekeringen. 2014. Webpage: http://www. fk.cvz.nl/.
15. Hakkaart-van Roijen L, Tan SS.,Bouwmans CAM. Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg, in: Handleideiding Voor Kostenonderzoek, 2010: pp. 3-126.
16. Tan SS, Bouwmans-frijters CAM, Roijen LH. Handleiding voor kostenonderzoek: methoden en referentieprijzen voor economische evaluaties in de gezondheidszorg. Tijdschrift Voor Gezondheidswetenschappen. 2012;90:367.72.
17. Utsunomiya D, Yanaga Y, Awai K, et al. Baseline incidence and severity of renal insufficiency evaluated by estimated glomerular filtration rates in patients scheduled for contrast-enhanced CT. Acta Radiol. 2011;52(1600) (Electronic):581-6.
18. Moos SI, van Vemde DNH, Stoker J, Bipat S. Contrast induced nephropathy in patients undergoing intravenous (IV) contrast enhanced computed tomography (CECT) and the relationship with risk factors: A meta-analysis. Eur J Radiol. 2013;29:1-13.
19. Kooiman J, Pasha SM, Zondag W, et al. Meta-analysis: serum creatinine changes following contrast enhanced CT imaging. Eur J Radiol. 2012;81:2554-61.